StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a research note published on Monday. The brokerage issued a sell rating on the biotechnology company’s stock.
Separately, Roth Mkm lowered their price objective on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, September 23rd.
Read Our Latest Stock Report on Aptevo Therapeutics
Aptevo Therapeutics Stock Performance
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.26. As a group, equities analysts predict that Aptevo Therapeutics will post -2.97 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 8.06% of the company’s stock.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Featured Stories
- Five stocks we like better than Aptevo Therapeutics
- What is a SEC Filing?
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- How to Read Stock Charts for Beginners
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- The 3 Best Fintech Stocks to Buy Now
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.